摘要
目的:富血小板血浆(platelet-rich plasma,PRP)关节腔内注射联合低负荷阻力训练(L-BFR)治疗膝关节软骨损伤的效果及对膝关节功能的影响。方法:选取2019年1月-2021年10月海安市中医院收治的120例膝关节软骨损伤患者作为研究对象,使用随机数字表法分为研究组和对照组,每组60例。对照组仅接受L-BFR,研究组接受PRP关节腔内注射联合L-BFR治疗。对比两组疼痛视觉模拟评分(VAS)、膝关节功能评分(Lysholm)、膝关节活动度及治疗效果。结果:研究组治疗3个月后VAS评分明显低于对照组,Lysholm评分与膝关节活动度均明显高于对照组,差异均有统计学意义(P<0.05)。研究组治疗总有效率为98.33%,高于对照组的78.33%(P<0.05)。结论:PRP关节腔内注射联合L-BFR治疗膝关节软骨损伤效果显著,可有效缓解患者的疼痛,提高膝关节的活动度,改善膝关节功能,可在膝关节软骨损伤患者中进行推广使用。
Objective:To study the effect of platelet-rich plasma(PRP)intra-articular injection combined with low load resistance training(L-BFR)on knee cartilage injury and its influence on knee joint function.Method:A total of 120 patients with knee cartilage injury admitted to the Obstetrics Department of Hai’an Hospital of Traditional Chinese Medicine from January 2019 to October 2021 were selected as the research objects,and they were divided into the study group and the control group by random number table method,60 patients in each group.The control group was only given L-BFR,and the study group was given PRP intra-articular injection combined with L-BFR.The pain visual analog scale(VAS),knee joint function score(Lysholm),knee joint range of motion and treatment effect were compared between two groups.Result:The VAS score of the study group after 3 months of treatment was significantly lower than that of the control group,the Lysholm score and knee joint range of motion were significantly higher than those of the control group,the differences were statistically significant(P<0.05).The total effective rate in the study group was 98.33%,which was higher than 78.33% in the control group(P<0.05).Conclusion:PRP intra-articular injection combined with L-BFR has a significant effect in the treatment of knee cartilage injury,which can effectively relieve the pain of patients,improve the range of motion of knee joint,and improve the function of knee joint,it can be popularized in patients with knee cartilage injury.
作者
管晓军
GUAN Xiaojun(Hai’an Hospital of Traditional Chinese Medicine,Jiangsu Province,Hai’an 226600,China)
出处
《中国医学创新》
CAS
2022年第10期31-34,共4页
Medical Innovation of China
基金
南通市基础研究和民生科技计划指导性项目(MSZ21114)。